With Dr. Joseph Rubinfeld joining the BOD, Amarantus now meets the Nasdaq uplist requirements for majority of board as Independent Directors.


Donald D. Huffman
Independent Director
Chairman of the Audit Committee

Robert L. Harris
Independent Director, Compliance Officer

Iain Ross
Independent Director

David A. Lowe, PhD

Gerald E. Commissiong
President & CEO

John W. Commissiong, PhD
Chief Scientific Officer